申请人:Omnichem Societe Anonyme
公开号:US04719208A1
公开(公告)日:1988-01-12
The invention is related to new 1,2,3,4,5,6-hexahydro-5-hydroyalkylazepino[4,5-b]-indole derivatives, of formula: ##STR1## in which R.sub.1 denotes a hydrogen atom, an alkyl radical, an alkenyl radical, a benzyl radical, an alkylamino radical of the type ##STR2## where the groups R' are either hydrogen atoms or alkyl radicals or form, together with the nitrogen atom to which they are attached, a heterocyclic nucleus of the morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl type, and m is 2 or 3, R.sub.2 denotes a hydrogen atom or a benzoyl or acyl radical, R.sub.3 denotes a hydrogen atom or an alkyl or benzyl radical, R.sub.4 denotes a hydrogen or halogen atom, an alkyl radical an alkoxy radical or a trifluoromethyl radical, and n is 1 or 2, and the salts of addition to pharmaceutically acceptable acids, and to process for their preparation, to intermediates obtained and to their therapeutical use in treating mental disorders.
这项发明涉及新的1,2,3,4,5,6-六氢-5-羟基烷基氮杂环[4,5-b]-吲哚衍生物,其化学式为:##STR1## 其中R.sub.1表示氢原子、烷基基团、烯基基团、苄基基团、类似##STR2##的烷基氨基基团,其中基团R'可以是氢原子或烷基基团,或者与它们连接的氮原子一起形成吗哒啉基、哌啶基、吡咯啉基或哌嗪基的杂环核,m为2或3,R.sub.2表示氢原子或苯甲酰基或酰基基团,R.sub.3表示氢原子或烷基或苄基基团,R.sub.4表示氢原子或卤素原子、烷基基团、烷氧基团或三氟甲基基团,n为1或2,以及其在制备药用可接受酸的加合物、制备过程、所得中间体和在治疗精神障碍中的治疗用途方面的用途。